Categories
Change Password!
Reset Password!
With long duration of action and long interval between
doses, Fremanezumab shows higher clinical efficacy than other treatments used
in the prevention of migraine.
With a significant reduction in the number of migraine days, average headache days per month and headache-associated disability, Fremanezumab exhibits considerable outcomes over placebo in 12-week trial. It was a double-blind, randomized, placebo-controlled, phase 3 trial, conducted to assess the efficacy, side-effect and safety profile of two subcutaneous dose treatment of Fremanezumab in preventing chronic migraine.
Selected patients were randomized to receive Fremanezumab
quarterly (625 mg medication at baseline and placebo at 4 and 8 week), monthly
(625 mg medication at baseline and 225 mg at 4 and 8 week) or matching placebo
subcutaneously. Following treatment, Fremanezumab monthly exhibited significant
a reduction in headache days per month followed by Fremanezumab quarterly and
placebo. Five patients from each Fremanezumab and three from placebo group
found with abnormalities in hepatic functionality. Altogether, Fremanezumab is a potent drug for
chronic migraine management, however, further investigation is required to
assess associated long-term safety and durability.
N Engl J Med. 2017 Nov 30;377(22):2113-2122
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
Comments (0)